Angiotensin converting enzyme gene polymorphism and ACE inhibition in diabetic nephropathy

Kidney International
P JacobsenH H Parving

Abstract

The antiproteinuric effect of angiotensin converting enzyme (ACE) inhibition in insulin-dependent diabetes mellitus (IDDM) patients with diabetic nephropathy varies considerably. Therefore, we tested the potential role of an insertion (I)/deletion (D) polymorphism of the ACE gene on this early antiproteinuric responsiveness in an observational follow-up study. Sixty (II, N = 13; ID, N = 26 and DD, N = 21) young hypertensive IDDM patients suffering from diabetic nephropathy were investigated during three months before and for the initial six month period during ACE inhibition [captopril 44 (SD 22) mg/24 hr, no differences in drug dose between groups]. Blood pressure (MABP) and albuminuria (ELISA) were measured three (1 to 6) times before and three (1 to 13) times during ACE inhibition. At baseline the groups (II/ID/DD) had comparable (1) mean arterial blood pressure (MABP mm Hg) of 113 +/- 10/108 +/- 9/114 +/- 8, (2) albuminuria (geometric mean with 95% CI) 1394 (747 to 2608)/1176 (844 to 1797) and 1261 (827 to 2017) mg/24 hr, and (3) serum creatinine (geometric mean with 95% CI), 80 (68 to 93)/85 (76 to 97)/103 (85 to 119) mumol/liter, respectively. Angiotensin converting enzyme inhibition induced a significant reduction in MAB...Continue Reading

References

Jan 1, 1976·Scandinavian Journal of Clinical and Laboratory Investigation·J Bröchner-Mortensen, P Rödbro
Aug 6, 1987·The New England Journal of Medicine·E FerranniniS Bevilacqua
Oct 1, 1985·Scandinavian Journal of Clinical and Laboratory Investigation·B Feldt-RasmussenM Deckert
Feb 1, 1996·Journal of the American Society of Nephrology : JASN·A SchmidtG Mayer
Sep 1, 1996·Kidney International·H YoshidaI Ichikawa

❮ Previous
Next ❯

Citations

Nov 13, 2004·Current Diabetes Reports·Errol D Crook, Sejal R Patel
Sep 12, 2000·Current Hypertension Reports·D B Corry, M L Tuck
Sep 12, 2000·Current Hypertension Reports·A B Fogo
Mar 16, 2004·Seminars in Nephrology·Hans-Henrik ParvingLise Tarnow
Apr 13, 2000·Pharmacology & Therapeutics·K Nakagawa, T Ishizaki
Mar 7, 2001·The Journal of Molecular Diagnostics : JMD·D Crisan, J Carr
Feb 7, 2003·The New England Journal of Medicine·William E Evans, Howard L McLeod
Dec 29, 2000·Current Opinion in Nephrology and Hypertension·M W Taal
Feb 9, 2012·Current Opinion in Nephrology and Hypertension·Merlin C ThomasKarl Tryggvason
Aug 13, 2005·Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences·Alun D McCarthyLefkos T Middleton
Nov 24, 2007·BioDrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy·B Kennon, J M Connell
Jun 27, 2002·American Journal of Pharmacogenomics : Genomics-related Research in Drug Development and Clinical Practice·J A Johnson
Jan 28, 2010·Expert Opinion on Drug Metabolism & Toxicology·Kim TaverneOlaf Klungel
Feb 28, 2002·The American Journal of the Medical Sciences·Errol D Crook
Feb 10, 2012·Kidney International·Hirofumi TomitaMasao Kakoki
Oct 16, 2004·Kidney International. Supplement·Peter Jacobsen, Hans-Henrik Parving
May 8, 2007·Diabetes Research and Clinical Practice·Elba LeivaMiguel Arredondo
Jul 31, 2002·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·Gert Mayer
Jan 6, 2012·Diabetes/metabolism Research and Reviews·Renato MillioniPaolo Tessari
Jun 18, 2004·Seminars in Perinatology·Gaurav KapurJ V Aranda
Sep 15, 2004·Diabetes Research and Clinical Practice·Masakazu HanedaUNKNOWN Candesartan in Diabetic Nephropathy Study Group
Mar 14, 2000·The Korean Journal of Internal Medicine·S Y HanH K Kim
Mar 29, 2005·Diabetes·Kevin Jon WilliamsKumar Sharma
Oct 20, 2012·Journal of Pharmacological Sciences·Paulo Caleb Junior Lima SantosAlexandre Costa Pereira
Jun 8, 2017·Journal of Cardiovascular Pharmacology and Therapeutics·Sergei M DanilovRandal O Dull
Jul 1, 2004·Expert Review of Cardiovascular Therapy·Norberto PericoGiuseppe Remuzzi
Aug 10, 2005·Journal of the Renin-angiotensin-aldosterone System : JRAAS·Peter Karl Jacobsen
Jan 4, 2007·Seminars in Cardiothoracic and Vascular Anesthesia·Robert B Yates, Mark Stafford-Smith
Feb 14, 2006·Journal of the Renin-angiotensin-aldosterone System : JRAAS·Peter Karl Jacobsen
Mar 7, 2002·Journal of the Renin-angiotensin-aldosterone System : JRAAS·T Elung-JensenN E Larsen
Jun 14, 2008·Clinical Journal of the American Society of Nephrology : CJASN·Piero RuggenentiGiuseppe Remuzzi
Jan 22, 2005·Journal of Hypertension·Martin C MichelRichard P Koopmans
Sep 29, 2000·Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association·S K HaD Suk Han
May 5, 2012·Journal of the Renin-angiotensin-aldosterone System : JRAAS·Rizk El-BazMohammed Abd El-Kader Sobh

❮ Previous
Next ❯

Related Concepts

Related Feeds

Autoimmune Diabetes & Tolerance

Patients with type I diabetes lack insulin-producing beta cells due to the loss of immunological tolerance and autoimmune disease. Discover the latest research on targeting tolerance to prevent diabetes.